Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

John Bennetts

Addiction Medicine Monterey, CA Medical Doctor

NPI 1477666345 CMS profile 111959

60 Garden Ct Ste 320, Monterey, CA 93940

Open in the dashboard

General payments

$5,419

246 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John Bennetts of Monterey, CA is reported in the CMS Open Payments database as having received $5,419 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,004 66
2021 General $1,405 65
2020 General $826 45
2019 General $2,185 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Bennetts
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to John Bennetts were reported at $0. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.

Show as a table
Year John Bennetts Addiction Medicine median Middle half National median
2019 $2,185 $96 $32–$265 $163
2020 $826 $53 $20–$176 $114
2021 $1,405 $86 $24–$265 $132
2022 $1,004 $89 $27–$330 $149
2023 $0 $102 $39–$363 $160
2024 $0 $110 $38–$311 $164
2025 $0 $147 $46–$381 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Lilly USA, LLC $1,174 9 payments
  2. AbbVie, Inc. $789 60 payments
  3. GlaxoSmithKline, LLC. $788 41 payments
  4. Sunovion Pharmaceuticals Inc. $385 19 payments
  5. Mylan Specialty L.P. $303 12 payments
  6. Abbott Laboratories $273 18 payments
  7. Allergan Inc. $256 17 payments
  8. Pfizer Inc. $215 17 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $160 6 payments
  10. Vertos Medical, Inc. $129 1 payment
  11. Other $948 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,408 244 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2019–2022
  1. CYMBALTA $1,000 1 payment
  2. VRAYLAR Neuroscience $486 35 payments
  3. TRELEGY ELLIPTA $358 17 payments
  4. ANORO ELLIPTA $330 18 payments
  5. LATUDA $258 11 payments
  6. FreeStyle Libre 2 $257 17 payments
  7. Yupelri $220 9 payments
  8. VRAYLAR Neuroscience $196 14 payments
  9. UBRELVY $158 15 payments
  10. TRULICITY $139 6 payments
  11. Other $3,076 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Family Medicine: 130

Drug cost

$186

Median for Family Medicine: $5,773

Branded share of claims

0%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 12 $186

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record